FibroGen (NASDAQ:FGEN) Given Market Perform Rating at William Blair

FibroGen (NASDAQ:FGEN)‘s stock had its “market perform” rating reissued by William Blair in a research note issued to investors on Tuesday,RTT News reports.

FGEN has been the subject of a number of other research reports. StockNews.com initiated coverage on FibroGen in a research report on Sunday. They set a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of FibroGen in a report on Tuesday, March 18th.

FibroGen Trading Up 0.7 %

NASDAQ:FGEN traded up $0.00 on Tuesday, hitting $0.31. 503,744 shares of the company’s stock traded hands, compared to its average volume of 2,325,241. The company has a market cap of $31.49 million, a PE ratio of -0.25 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.40. The firm has a 50-day moving average price of $0.46 and a 200-day moving average price of $0.43.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million. On average, research analysts forecast that FibroGen will post -0.8 EPS for the current fiscal year.

Insider Activity at FibroGen

In other news, CEO Thane Wettig purchased 145,000 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $0.35 per share, with a total value of $50,750.00. Following the completion of the transaction, the chief executive officer now directly owns 543,329 shares in the company, valued at $190,165.15. This trade represents a 36.40 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James A. Schoeneck acquired 250,000 shares of FibroGen stock in a transaction dated Thursday, March 20th. The stock was purchased at an average price of $0.35 per share, with a total value of $87,500.00. Following the completion of the purchase, the director now directly owns 323,722 shares of the company’s stock, valued at $113,302.70. The trade was a 339.11 % increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Two Sigma Securities LLC acquired a new stake in shares of FibroGen in the fourth quarter valued at about $27,000. Velan Capital Investment Management LP acquired a new stake in FibroGen in the 4th quarter valued at approximately $42,000. XTX Topco Ltd increased its position in FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC lifted its holdings in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 100,000 shares during the last quarter. Finally, FMR LLC boosted its position in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the period. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.